Heparin-sorbent for low density lipoproteins removal in hypercholesterolemia

Biomaterials, Artificial Cells, and Artificial Organs
V V SinitsynV V Kukharchuk

Abstract

Heparin-sorbent was developed in the USSR Cardiology Research Center for LDL-apheresis in patients with familial hypercholesterolemia. Clinical trials of the sorbent were started in 1985. Heparin-sorbent has a high capacity for LDL. One column (400ml) can remove 3 - 6g of LDL cholesterol, depending on the initial LDL content in the plasma. The sorbent demonstrates a high stability, it can withstand more then 75 sorbtion-desorbtion cycles with only a slight loss of the initial capacity. It means that one column can work for 1,5-2,0 years when used weekly. Heparin-sorbent is the sorbent of limited selectivity, apo-B content in eluate is 40-60% of the total protein content, but it is important that it does not bind HDL.

References

Mar 22, 1976·Biochemical and Biophysical Research Communications·L H LamR D Rosenberg
Oct 1, 1968·Proceedings of the National Academy of Sciences of the United States of America·P CuatrecasasC B Anfinsen
May 1, 1984·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·S YokoyamaA Yamamoto

❮ Previous
Next ❯

Citations

Jan 7, 2005·Macromolecular Bioscience·Handan Yavuz, Adil Denizli
Jun 17, 2003·Journal of Biomaterials Science. Polymer Edition·Handan Yavuz, Adil Denizli

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.